Laboratorios [ROVI] vs Grifols, S.A [GRF] Detailed Stock Comparison

Laboratorios

BME
Loading...

Grifols, S.A

BME
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Laboratorios wins in 9 metrics, Grifols, S.A wins in 10 metrics, with 0 ties. Grifols, S.A appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricLaboratoriosGrifols, S.ABetter
P/E Ratio (TTM)23.3827.07Laboratorios
Price-to-Book Ratio5.501.57Grifols, S.A
Debt-to-Equity Ratio22.50126.87Laboratorios
PEG Ratio22.3420.19Grifols, S.A
EV/EBITDA16.4011.29Grifols, S.A
Profit Margin (TTM)17.66%4.00%Laboratorios
Operating Margin (TTM)17.14%18.48%Grifols, S.A
EBITDA Margin (TTM)17.14%18.48%Grifols, S.A
Return on Equity25.01%4.99%Laboratorios
Return on Assets (TTM)12.50%4.43%Laboratorios
Free Cash Flow (TTM)$76.06M$530.80MGrifols, S.A
Dividend Yield1.69%N/AN/A
1-Year Return-18.56%17.34%Grifols, S.A
Price-to-Sales Ratio (TTM)4.140.96Grifols, S.A
Enterprise Value$3.19B$19.59BGrifols, S.A
EV/Revenue Ratio4.262.63Grifols, S.A
Gross Profit Margin (TTM)65.93%39.33%Laboratorios
Revenue per Share (TTM)$15$11Laboratorios
Earnings per Share (Diluted)$2.59$0.44Laboratorios
Beta (Stock Volatility)0.470.98Laboratorios
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Laboratorios vs Grifols, S.A Stock Performance Analysis

Loading Price Chart...

Laboratorios
Grifols, S.A
Laboratorios Stock Overview | Grifols, S.A Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Laboratorios-0.26%-1.84%1.82%8.89%11.79%-8.13%
Grifols, S.A2.81%-0.83%-3.95%17.57%29.60%25.90%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Laboratorios-18.56%33.03%89.68%340.12%1,064.36%511.23%
Grifols, S.A17.34%34.12%-52.40%-36.11%126.86%358.08%

News Based Sentiment: Laboratorios vs Grifols, S.A

Laboratorios

News based Sentiment: MIXED

September was a month of contrasts for ROVI, with positive stock performance on certain days and strong analyst optimism, but also tempered by lower half-year results and anticipated earnings declines. The company remains significantly undervalued according to multiple analyses, creating a complex investment picture.

View Laboratorios News Sentiment Analysis

Grifols, S.A

News based Sentiment: MIXED

September presented a mixed bag for Grifols, with positive analyst revisions and promising research developments offset by market volatility and concerns about revenue forecasts. While the company demonstrates growth and innovation, it faces scrutiny and market headwinds, making it a cautiously optimistic investment.

View Grifols, S.A News Sentiment Analysis

Performance & Financial Health Analysis: Laboratorios vs Grifols, S.A

MetricROVIGRF
Market Information
Market Cap i€3.04B€7.45B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i151,313971,398
90 Day Avg. Volume i118,4261,094,871
Last Close€58.65€12.24
52 Week Range€45.52 - €80.20€7.32 - €13.70
% from 52W High-26.87%-10.62%
All-Time High€94.80 (May 27, 2024)€34.31 (Feb 17, 2020)
% from All-Time High-38.13%-64.33%
Growth Metrics
Quarterly Revenue Growth-0.10%0.04%
Quarterly Earnings Growth-0.26%6.89%
Financial Health
Profit Margin (TTM) i0.18%0.04%
Operating Margin (TTM) i0.17%0.18%
Return on Equity (TTM) i0.25%0.05%
Debt to Equity (MRQ) i22.50126.87
Cash & Liquidity
Book Value per Share (MRQ)€11.02€7.60
Cash per Share (MRQ)€0.93€0.86
Operating Cash Flow (TTM) i€136.55M€1.10B
Levered Free Cash Flow (TTM) i€7.13M€718.49M
Dividends
Last 12-Month Dividend Yield i1.69%N/A
Last 12-Month Dividend i€0.94€0.00

Valuation & Enterprise Metrics Analysis: Laboratorios vs Grifols, S.A

MetricROVIGRF
Price Ratios
P/E Ratio (TTM) i23.3827.07
Forward P/E i22.3420.19
PEG Ratio i22.3420.19
Price to Sales (TTM) i4.140.96
Price to Book (MRQ) i5.501.57
Market Capitalization
Market Capitalization i€3.04B€7.45B
Enterprise Value i€3.19B€19.59B
Enterprise Value Metrics
Enterprise to Revenue i4.262.63
Enterprise to EBITDA i16.4011.29
Risk & Other Metrics
Beta i0.470.98
Book Value per Share (MRQ) i€11.02€7.60

Financial Statements Comparison: Laboratorios vs Grifols, S.A

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)ROVIGRF
Revenue/Sales i€154.89M€1.89B
Cost of Goods Sold i€64.49M€1.15B
Gross Profit i€90.40M€743.80M
Research & Development iN/A€96.19M
Operating Income (EBIT) i€23.10M€349.54M
EBITDA i€30.92M€355.88M
Pre-Tax Income i€22.85M€190.51M
Income Tax i€4.77M€52.13M
Net Income (Profit) i€18.08M€138.38M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)ROVIGRF
Cash & Equivalents i€29.31M€558.69M
Total Current Assets i€467.86M€5.25B
Total Current Liabilities i€126.28M€1.99B
Long-Term Debt i€85.27M€8.43B
Total Shareholders Equity i€599.47M€7.60B
Retained Earnings i€503.43M€176.79M
Property, Plant & Equipment iN/A€6.57B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)ROVIGRF
Operating Cash Flow i€54.81M€1.22B
Capital Expenditures i€-8.06MN/A
Free Cash Flow i€10.57M€371.87M
Debt Repayment i€-6.22MN/A
Common Stock Repurchase i€-14.69MN/A

Short Interest & Institutional Ownership Analysis

MetricROVIGRF
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i151,313971,398
Average Daily Volume (90 Day) i118,4261,094,871
Shares Outstanding i51.15M680.41M
Float Shares i16.65M561.06M
% Held by Insiders i0.67%0.31%
% Held by Institutions i0.17%0.30%

Dividend Analysis & Yield Comparison: Laboratorios vs Grifols, S.A

MetricROVIGRF
Last 12-Month Dividend i€0.94€0.00
Last 12-Month Dividend Yield i1.69%N/A
3-Year Avg Annual Dividend i€1.11€0.00
3-Year Avg Dividend Yield i2.08%N/A
3-Year Total Dividends i€3.33€0.00
Ex-Dividend DateJul 14, 2025N/A